Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 03589W102 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| State Street Corp 13G | 6.0% |
8/7/2026
Event 6/30/2026
|
|
| BlackRock, Inc. 13G/A Amendment 2 | 8.0% |
7/27/2026
Event 6/30/2026
|
|
|
Redmile Group, LLC
13G/A
Amendment 6
|
9.9% |
7/8/2026
Event 7/1/2026
|
|
| Redmile Group, LLC | 9.9% | ||
| Jeremy C. Green | 9.9% | ||
| RedCo II Offshore SPV LLC | 5.5% | ||
|
FMR LLC
13G/A
Amendment 6
|
11.9% |
7/8/2026
Event 6/30/2026
|
|
| FMR LLC | 11.9% | ||
| Abigail P. Johnson | 11.9% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 4
|
5.4% |
5/15/2026
Event 3/31/2026
|
|
| Biotechnology Value Fund L P | 2.9% | ||
| BVF I GP LLC | 2.9% | ||
| Biotechnology Value Fund II LP | 2.1% | ||
| BVF II GP LLC | 2.1% | ||
| Biotechnology Value Trading Fund OS LP | 0.3% | ||
| BVF Partners OS Ltd. | 0.3% | ||
| BVF GP Holdings LLC | 5.0% | ||
| BVF Partners L P/IL | 5.4% | ||
| BVF Inc/IL | 5.4% | ||
| Lampert Mark N | 5.4% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/26/2026
Event 3/13/2026
|
|
|
Redmile Group, LLC
13G/A
Amendment 5
|
9.9%
Checked 5% or less
|
2/17/2026
Event 12/31/2025
|
|
| Redmile Group, LLC | 9.9% | ||
| Jeremy C. Green | 9.9% | ||
| Redmile Biopharma Investments II, L.P. | 4.7% | ||
|
FMR LLC
13G/A
Amendment 5
|
7.1% |
2/5/2026
Event 12/31/2025
|
|
| FMR LLC | 7.1% | ||
| Abigail P. Johnson | 7.1% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 6.1% |
1/21/2026
Event 12/31/2025
|
|
| Satter Muneer A 13D/A Amendment 2 | 7.2% |
11/21/2025
Event 11/19/2025
|
|
|
FMR LLC
13G/A
Amendment 4
|
10.1% |
11/5/2025
Event 9/30/2025
|
|
| FMR LLC | 10.1% | ||
| Abigail P. Johnson | 10.1% | ||
| Vanguard Group Inc 13G | 5.3% |
10/30/2025
Event 9/30/2025
|
|
|
Logos Global Management LP
13G/A
Amendment 1
|
0% |
8/14/2025
Event 6/30/2025
|
|
| Logos Global Management LP | 0% | ||
| Logos Global Management GP LLC | 0% | ||
| Logos Global Master Fund LP | 0% | ||
| Logos GP LLC | 0% | ||
| Arsani William | 0% | ||
|
FMR LLC
13G/A
Amendment 3
|
14.3% |
8/6/2025
Event 6/30/2025
|
|
| FMR LLC | 14.3% | ||
| Abigail P. Johnson | 14.3% | ||
|
Point72 Asset Management, L.P.
13G/A
Amendment 1
|
0.1% |
5/15/2025
Event 3/31/2025
|
|
| Point72 Asset Management, L.P. | 0.1% | ||
| Point72 Capital Advisors, Inc. | 0.1% | ||
| Steven A. Cohen | 0.1% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 4.9% |
4/30/2025
Event 3/31/2025
|
|
|
Logos Global Management LP
13G
|
6.0% |
4/28/2025
Event 4/21/2025
|
|
| Logos Global Management LP | 6.0% | ||
| Logos Global Management GP LLC | 6.0% | ||
| Logos Global Master Fund LP | 6.0% | ||
| Logos GP LLC | 6.0% | ||
| Arsani William | 6.0% | ||
|
Bain Capital Life Sciences Fund, L.P.
13G/A
Amendment 5
|
4.9% |
2/14/2025
Event 12/31/2024
|
|
| BCLS I Investco, LP | 4.9% | ||
| BCIP Life Sciences Associates, LP | 0% | ||
| Bain Capital Life Sciences Fund, L.P. | 0% | ||
| Vanguard Group Inc 13G | 5.2% |
1/31/2025
Event 12/31/2024
|
|
|
FMR LLC
13G/A
Amendment 2
|
13.1% |
12/6/2024
Event 11/29/2024
|
|
| FMR LLC | 13.1% | ||
| Abigail P. Johnson | 13.1% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 15.8 k | $67.0 k |
| 2026 Q2 | 229 | 179 M | $1.15 B |
| 2026 Q1 | 226 | 156 M | $864 M |
| 2025 Q4 | 181 | 137 M | $688 M |
| 2025 Q3 | 151 | 101 M | $309 M |
| 2025 Q2 | 133 | 100 M | $239 M |
| 2025 Q1 | 154 | 99.8 M | $192 M |
| 2024 Q4 | 158 | 112 M | $575 M |
| 2024 Q3 | 148 | 112 M | $661 M |
| 2024 Q2 | 163 | 114 M | $556 M |
| 2024 Q1 | 143 | 97.8 M | $699 M |
| 2023 Q4 | 108 | 81.3 M | $368 M |
| 2023 Q3 | 100 | 53.6 M | $126 M |
| 2023 Q2 | 103 | 54.1 M | $190 M |
| 2023 Q1 | 106 | 54.0 M | $208 M |
| 2022 Q4 | 93 | 48.5 M | $244 M |
| 2022 Q3 | 79 | 47.6 M | $292 M |
| 2022 Q2 | 85 | 38.4 M | $145 M |
| 2022 Q1 | 106 | 38.8 M | $106 M |
| 2021 Q4 | 103 | 38.8 M | $446 M |
| 2021 Q3 | 84 | 38.1 M | $709 M |
| 2021 Q2 | 76 | 38.9 M | $874 M |
| 2021 Q1 | 74 | 37.4 M | $1.04 B |
| 2020 Q4 | 72 | 36.2 M | $904 M |
| 2020 Q3 | 68 | 34.8 M | $1.04 B |